Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster ...

Moderna said the changes will reduce the cumulative spend on R&D between 2025 and 2028 to $16 billion from $20 billion, and ...

Among the key problems highlighted in the report is that too much of the NHS budget is being spent in hospitals, with too ...

Taking the previous Conservative government to task, Starmer highlighted the long-term impact of the 2012 Health and Social Care Act – described by Darzi as "a calamity without international precedent ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health. Executives from AstraZeneca, ...

Last month, the US Centers for Medicare and Medicaid Services released the negotiated prices for the first 10 drugs subject to the drug negotiation provisions in the Inflation Reduction Act. The ...

The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures. Ben Hargreaves finds that a new variant of the virus is spreading more rapidly, and the response is ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World ...

In the study, MILTON was used to analyse 3,200 diseases and achieved a high prediction score for 1,091 of them. It can be ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...

At the European Respiratory Society (ERS) congress in Vienna, Loes van Bemmel of Maastricht University Medical Center in the ...